Notwithstanding the decline which has been observed in recent years, circulatory diseases
continue to be the leading cause of death in Brazil.[1] In spite of recent advances in clinical and interventional
treatment,[2],[3]
ischemic heart disease (IHD) was responsible for 116,333 deaths in 2016, of which 80%
were due to acute manifestations, principally in the form of acute myocardial infarction
(AMI).[4]In treating AMI patients, especially those with ST-segment elevation, the pre-hospital
phase of care plays a crucial role in short- and long-term prognosis. Two data related
to this phase deserve our attention. First, we may observe delays in reaching healthcare
services. In 80% of cases, these delays last for more than two hours starting from the
moment symptoms begin to manifest.[2],[3]
Second, it stands out that 50% of deaths resulting from AMI were recorded precisely
during the pre-hospital phase.[2],[3]Whether these delays in reaching pre-hospital care are predominantly patient-related,
including, among other factors, difficulties in recognizing and interpreting symptoms
owing to socioeconomic status and/or cultural factors, or whether they are associated
with a lack of efficiency within the healthcare system, for example in transporting
patients from the place where symptoms onset to the final destination, i.e. the
hospital, has yet to be established in the literature.[4] It is also important to highlight that a recent study
indicated that there are sex-specific differences, with greater delays being observed in
women, mainly owing to atypical symptoms which lead to delays in the decision to seek
healthcare.[5]Several factors have been associated with delays during the pre-hospital phase, including
non-white ethnicity; low socioeconomic status; cultural factors; previous history of
angina, diabetes, or hypertension; sociodemographic and situational factors, for
example, distance to treatment centers or medical consultation conducted by spouses or
relatives; lack of knowledge regarding the meaning of symptoms; anxiety caused by
symptoms; access to public and private healthcare systems; the time of day/night when
symptoms onset; previous infarction, and associated symptoms, such as profuse sweating,
arterial hypotension, and intensity of precordial pain severity.[6]-[8]In Brazil, Rodrigues et al. published a study on predictors of late presentation in 1,297
patients with AMI in a referral center in the country’s South Region, which is able to
perform primary angioplasty 24 hours a day, seven days a week.[9] Approximately 25% (n = 302) of the total patients
attended between December 2009 and November 2014 presented a delay of more than six
hours, with a significantly higher mortality rate. The independent predictors of late
presentation were: black ethnicity, low income level (less than five times minimum
wage), and diabetes mellitus. The following variables lost statistical significance
after adjusting for multiple logistic regression analysis: female sex, less than eight
years of schooling, and occurrence of chronic renal failure. Patients with all of the
independent predictors of late presentation took twice as long to reach the hospital as
other patients. History of previous heart disease, AMI, or myocardial revascularization
were protective factors,[9] likely owing
to the early recognition of a new event and, thus, to reduced delays in seeking medical
treatment.Unfortunately, the authors of this study did not record the distance between the place
where symptoms onset and the referral center; they also excluded transfer patients in
order to evaluate spontaneous demand.[9]
These two factors also influence mortality related to the pre-hospital phase, even
though they are dependent on the healthcare system. On the other hand, they also did not
analyze the following confounding factors which are related both to distance between
place of symptoms onset and referral center and to transfer patients: ventricular
function, time taken to implement mechanical or drug reperfusion therapy, reperfusion
therapy success rate, associated procedures, and implementation of adjuvant therapy
recommended in the guidelines.[2],[3]It is also noteworthy that overall mortality differed significantly between the two
groups studied, there being no differences observed regarding subgroups, even with major
cardiovascular events. This leads us to suppose that other factors that were not
analyzed influenced 30-day mortality rate, for instance, mortality related to the
performance of highly complex procedures.One recent study suggests that higher mortality in women due to delays during the
pre-hospital phase may be due to the fact that women appear to be more vulnerable to
prolonged untreated ischemia.[10] The
longest delays in this study were related to the healthcare system. The authors stress
that mortality was even higher in those who arrived at the hospital with more than
twelve hours’ delay, as they did not receive any form of reperfusion therapy. In the
study carried out by Rodrigues et al., these patients were excluded, thus making it
impossible to establish a comparison.[9]Cultural differences regarding attitudes toward AMI symptoms are also relevant
patient-dependent factors. A recent study carried out in Japan showed that patients who
were men, were elderly, had lower levels of schooling and had lower self-confidence
regarding their understanding of AMI would present delays in seeking medical
treatment.[11] These
patient-related factors were also absent from Rodrigues et al.[9]It is important to highlight that the results of the study carried out by Rodrigues et
al. come from a single center whose conditions are quite rare in Brazil, which
demonstrates that the continuous availability of mechanical reperfusion therapy was not
sufficient to reduce the 30-day AMI mortality rate of about 10% in patients who arrived
at the hospital with more than six hours’ delay following onset of symptoms. This is an
additional conclusion to the data presented by the authors.It is necessary to invest not only in the availability of excellent mechanical
reperfusion therapy, but also in equal access to healthcare systems, both by improving
the population’s socio-economic and cultural conditions and by implementing thrombolytic
therapy close to the place where the patient is located during the onset of symptoms or
in pre-hospital transport. Only then will we be able to make the mortality rates we
observe in our clinical practice match the ones described in the clinical trials of the
guidelines.
Authors: Fernando Rivero; Teresa Bastante; Javier Cuesta; Amparo Benedicto; Jorge Salamanca; Jorge-Andrés Restrepo; Río Aguilar; Federico Gordo; Maurice Batlle; Fernando Alfonso Journal: Rev Esp Cardiol (Engl Ed) Date: 2015-12-04
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Bruno Ramos Nascimento; Luisa Campos Caldeira Brant; Gláucia Maria Moraes de Oliveira; Marcus Vinícius Bolívar Malachias; Gabriel Moreira Alves Reis; Renato Azeredo Teixeira; Deborah Carvalho Malta; Elisabeth França; Maria de Fátima Marinho Souza; Gregory A Roth; Antonio Luiz P Ribeiro Journal: Arq Bras Cardiol Date: 2018-06 Impact factor: 2.000
Authors: Sofia Sederholm Lawesson; Rose-Marie Isaksson; Maria Ericsson; Karin Ängerud; Ingela Thylén Journal: BMJ Open Date: 2018-05-03 Impact factor: 2.692